Browsing Tag
Ionis Pharmaceuticals Inc.
2 posts
Zanvastro approval validates Ionis Pharmaceuticals neurology strategy, but how large is the market?
Ionis Pharmaceuticals has secured the first FDA approval for Alexander disease with Zanvastro, a quarterly RNA-targeted treatment priced at $285,000 per dose, while the ultra-rare population limits its standalone commercial ceiling.
Why did Corcept, Johnson & Johnson, and Southwest Airlines fall on April 1, 2025?
Corcept, Johnson & Johnson, and Southwest Airlines lead US stock losses as biotech and airline sectors react to trade policy jitters on April 1, 2025.